Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff

Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff

Abstract Background Breast cancer was previously categorized as human epidermal growth factor receptor 2 (HER2)-positive (immunohistochemistry [IHC] 3+, IHC 2+ / in situ hybridization [ISH]–positive) or HER2-negative (IHC 0, IHC 1+, IHC 2+/ISH−). Recent studies of trastuzumab deruxtecan, a HER2-dire...

Full description

Saved in:
Bibliographic Details
Main Authors: Agata Wróbel, Michel Vandenberghe, Marietta Scott, Frances Jones, Tsuyoshi Matsuo, Anne-Marie Boothman, Jessica Whiteley, Craig Barker
Format: Article
Language:English
Published: BMC 2025-04-01
Series:Diagnostic Pathology
Subjects:
Breast cancer
HER2-low
HER2-ultralow
Immunohistochemistry
Scoring
Online Access:https://doi.org/10.1186/s13000-025-01624-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13000-025-01624-3

Similar Items